Mobocertinib

105 interactions 10 explained in plain English
Also sold as: Exkivity
Dr. Brian Staiger, PharmD, BCPS
Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Jul 4, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Ketoconazole Topical Lefamulin Medroxyprogesterone Clindamycin Topical Metronidazole Topical Oxaliplatin Injection
2 Contraindicated 100 Major 3 Moderate
All (105) Contraindicated (2) Major (100) Moderate (3)

Major

Mobocertinib Mefloquine Lariam® An increased risk of QT interval prolongation Details Mobocertinib Metronidazole Flagyl An increased risk of QT interval prolongation Details Mobocertinib Metronidazole Injection Flagyl An increased risk of QT interval prolongation Details Mobocertinib Metronidazole Topical MetroCream® An increased risk of QT interval prolongation Details Mobocertinib Metronidazole Vaginal MetroGel® Vaginal An increased risk of QT interval prolongation Details Mobocertinib Midostaurin Rydapt Decreased plasma concentrations of the CYP3A substrate, which may result in serious therapeutic failure Details Mobocertinib Mitapivat Aqvesme Reduced CYP3A substrate exposure Details Mobocertinib Moxifloxacin Avelox An increased risk of QT interval prolongation Details Mobocertinib Moxifloxacin Injection Avelox An increased risk of QT interval prolongation Details Mobocertinib Moxifloxacin Ophthalmic Moxeza® An increased risk of QT interval prolongation Details Mobocertinib Nafarelin Nasal Spray Synarel An increased risk of QT interval prolongation Details Mobocertinib Nafcillin Injection Unipen® Injection Reduced mobocertinib exposure and risk of reduction of the anti-tumor activity of mobocertinib Details Mobocertinib Neratinib Nerlynx Decreased plasma concentrations of the CYP3A substrate, which may result in serious therapeutic failure Details Mobocertinib Nifedipine Adalat® Reduced NIFEdipine exposure Details Mobocertinib Octreotide Bynfezia An increased risk of QT interval prolongation Details Mobocertinib Octreotide Injection Bynfezia An increased risk of QT interval prolongation Details Mobocertinib Ofloxacin Floxin® An increased risk of QT interval prolongation Details Mobocertinib Ofloxacin Ophthalmic Ocuflox An increased risk of QT interval prolongation Details Mobocertinib Ofloxacin Otic Floxin® Otic An increased risk of QT interval prolongation Details Mobocertinib Olaparib Lynparza Decreased plasma concentrations of the CYP3A substrate, which may result in serious therapeutic failure Details Mobocertinib Olodaterol Oral Inhalation Striverdi An increased risk of QT interval prolongation and an increased risk of ventricular arrhythmias Details Mobocertinib Oxaliplatin Injection Eloxatin® An increased risk of QT interval prolongation Details

Moderate

Mobocertinib Trospium / Xanomeline Cobenfy Explained Increased oral sensitive CYP3A4 substrate exposure and an increased risk on severity and frequency of sensitive CYP3A4 substrate-r... Details Mobocertinib Hydrocortisone Ala-Cort Reduced hydrocortisone exposure Details Mobocertinib Hydrocortisone Injection A-Hydrocort® Reduced hydrocortisone exposure Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist
Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.